denkapparat Operations GmbH Purchases Shares of 18,204 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

denkapparat Operations GmbH acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,204 shares of the biopharmaceutical company’s stock, valued at approximately $171,000.

Other hedge funds have also made changes to their positions in the company. Norges Bank purchased a new position in Amicus Therapeutics during the fourth quarter worth about $29,033,000. Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after acquiring an additional 2,856,101 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $13,530,000. Vanguard Group Inc. grew its holdings in Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after purchasing an additional 458,143 shares during the period. Finally, Rice Hall James & Associates LLC increased its position in Amicus Therapeutics by 41.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after purchasing an additional 398,942 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on FOLD. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Wells Fargo & Company lowered their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Finally, StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Performance

Amicus Therapeutics stock opened at $8.43 on Friday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a one year low of $8.36 and a one year high of $12.65. The stock’s 50 day moving average price is $9.28 and its 200 day moving average price is $9.97. The firm has a market capitalization of $2.59 billion, a PE ratio of -46.83, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.